Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Ankylosing Spondylitis is an inflammatory arthritis that affects the spine and sacroiliac joints as well as other parts of the body, and that can eventually lead, in some patients, to complete fusion of the vertebrae and total rigidity. AS is not a rare health problem, but is in fact found in almost one percent of the US population, typically strikes young people and young families, and in its various forms is probably more common than rheumatoid arthritis. In this invaluable guide, Dr. Michael H. Weisman, one of America's leading authorities on AS, provides a down-to-earth, crystal-clear guid

Ankylosing spondylitis

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Spondylitis, Ankylosing

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Ankylosing Spondylitis - Recent Concepts provides a comprehensive overview of ankylosing spondylitis (AS). It includes five chapters organized into two sections. The first section is dedicated to the history of AS, the chronology of diagnostic/classification criteria across the years, and imaging in AS. The second section examines the molecular genetics, immunology, enteric microbiome, and pharmacologic and nonpharmacologic treatment.

Ankylosing spondylitis.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Ankylosing spondylitis --- Spondylitis --- History --- History

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by inflammation of the spine and pelvic joint. It usually strikes people in their late teens and continues for the rest of their life. SA was strongly associated with human leukocyte antigen (HLA B27). The pharmacological treatment methods in spondylitis are highly dependent on the use of non-steroidal anti-inflammatory drugs (NSAIDs). They are effective in improving symptoms, but are not effective in delaying the progression of the disease. In addition, DMARDs such as sulfasalazine or methotrexate, which are used in patients who do not respond to NASIDs, reduce peripheral symptoms, but they are less effective in treating the symptoms of the axial skeleton. In recent decades, several studies have shown that anti-TNF-alpha (infliximab, etanercept, adalimumab and golimumab) can significantly reduce inflammation, slow bone destruction ant they have helped many patients to find a near-normal quality of life La spondylarthrite ankylosante (SA) est une maladie inflammatoire chronique frappant surtout la colonne vertébrale et les articulations sacro-iliaques. Elle début généralement à la fin de l’adolescence pour se poursuivre le reste de la vie. La SA a été fortement associées à l’antigène leucocytaire humain (HLA B27). La prise en charge optimale des patients atteints de la SA nécessite une combinaison entre des traitements non-pharmacologiques et des traitements pharmacologiques. L’approche pharmacologique comprend l’utilisation d’anti-inflammatoire non stéroïdiens (AINS). Ils sont efficaces pour améliorer les symptômes, mais ne sont pas efficaces pour retarder la progression de la maladie. En outre, les DMARDS tels que la sulfasalazine ou le méthotrexate, qui sont utilisés chez les patients qui ne répondent pas aux AINS, réduisent les symptômes périphériques, mais ils sont moins efficaces dans le traitement des symptômes du squelette axial. Au cours de ces dernières décennies, plusieurs études ont montré que les anti-tnf-alphas (infliximab, étanercept, adalimumab et golimumab) permettent de réduire considérablement l’inflammation, de ralentir les destructions osseuses et ils ont permis à de nombreux malades de retrouver une qualité de vie quasi normale

Biological Therapy --- Spondylitis, Ankylosing